Coronavirus disease-19 caused by the novel RNA betacoronavirus SARS-CoV2 has first emerged in Wuhan, China in December 2019, and since then developed into a worldwide pandemic with >99 million people afflicted and >2.1 million fatal outcomes as of 24th January 2021. SARS-CoV2 targets the lower respiratory tract system leading to pneumonia with fever, cough, and dyspnea. Most patients develop only mild symptoms. However, a certain percentage develop severe symptoms with dyspnea, hypoxia, and lung involvement which can further progress to a critical stage where respiratory support due to respiratory failure is required. Most of the COVID-19 symptoms are related to hyperinflammation as seen in cytokine release syndrome and it is believed that fatalities are due to a COVID-19 related cytokine storm. Treatments with anti-inflammatory or anti-viral drugs are still in clinical trials or could not reduce mortality. This makes it necessary to develop novel anti-inflammatory therapies. Recently, the therapeutic potential of phytocannabinoids, the unique active compounds of the cannabis plant, has been discovered in the area of immunology. Phytocannabinoids are a group of terpenophenolic compounds which biological functions are conveyed by their interactions with the endocannabinoid system in humans. Here, we explore the anti-inflammatory function of cannabinoids in relation to inflammatory events that happen during severe COVID-19 disease, and how cannabinoids might help to prevent the progression from mild to severe disease.
【저자키워드】 COVID-19, Inflammation, Cytokine storm, SARS-CoV2, cannabis, Cytokine release syndrome, cannabinoids, cannabinoid receptors, 【초록키워드】 immunology, clinical trial, Respiratory failure, Mortality, Anti-inflammatory, hypoxia, Pneumonia, lung involvement, progression, outcome, cough, Betacoronavirus, RNA, biological function, humans, hyperinflammation, Fever, Dyspnea, Mild, target, Critical, anti-viral drug, mild symptoms, severe COVID-19 disease, fatality, Interaction, Inflammatory, severe disease, Respiratory Support, Lower respiratory tract, COVID-19 symptom, worldwide pandemic, Compound, therapeutic potential, help, anti-inflammatory therapies, anti-inflammatory function, MOST, Prevent, event, Wuhan, China, develop, caused, required, Most patient, unique, severe symptom, not reduce, 【제목키워드】 paradigm,